

Induction of original phenotype of human immortalized chondrocytes: A quantitative gene expression analysis

LIVIA ROSETTI¹, ANDREA FACCHINI^{1,2}, LUCIANA DE FRANCESCHI¹,
EMANUELE MARCONI¹, EUGENE O. MAJOR³ and BRUNELLA GRIGOLO¹

¹Laboratorio di Immunologia e Genetica, Istituto di Ricerca Codivilla Putti, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, ²Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy; ³Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD 20892-4164, USA

Received May 15, 2006; Accepted July 7, 2006

Abstract. We previously established a line of immortalized normal human articular chondrocytes, lbpva55, expressing the E6 and E7 transforming genes of the human papilloma virus type 16. With this study we investigated the phenotypic modulation ability of this cell line, cultured in different conditions, with the aim of validating its use for studies on cartilage metabolism and physiology. To this end, we performed a quantitative analysis, using real-time PCR technology, of the expression of the main structural components of the cartilage matrix (collagens I, II and aggrecan), of two transcription factors regulating chondrocyte differentiation (Sox-9 and Egr-1) and of some enzymes involved in matrix turnover (cathepsin B, MMP-1 and MMP-13). Results showed that, under defined conditions, lbpva55 cells were able to re-express the chondrocyte phenotype that was lost in a conventional monolayer condition, as demonstrated by an up-regulation of collagen II, the main marker of hyaline cartilage and Sox-9, a master gene regulator of chondrocytic differentiation. The gene expression profile of our immortalized cells compared with that of normal articular chondrocytes showed that this line could be used as a valid *in vitro* model for a better understanding of cell molecular mechanisms relevant for the development of new therapeutic approaches in rheumatic diseases and for the cartilage engineering field.

Introduction

The model of monolayer cultured chondrocytes has been widely used to understand the mechanisms involved in normal cartilage matrix turnover and cell differentiation and how these may be perturbed in arthritic conditions (1-3). However, detailed biochemical and molecular studies have been hampered by a number of factors such as the scarce availability of tissue and its weak cellularity. More importantly, chondrocytes expanded in monolayer display a high phenotypic instability and inherent heterogeneity within cultures (4-8). It is well known that, starting from the first passages after isolation, chondrocyte cells undergo a de-differentiation process which involves significant changes in their phenotype and results principally in the down-regulation of collagen II and aggrecan and in the up-regulation of collagens I and III expressed in prechondrogenic mesenchymal cells (9-11). The use of chondrocytes of human origin is even more difficult due to the higher variability of the specimens (age and condition of patients) and the phenotypic liability of the cells once they are in culture, besides a number of legal and ethical problems.

In the last few years researchers have developed many alternative *in vitro* systems which may allow chondrocyte phenotype stabilization, such as alginate beads (12) pellet cultures (13), the use of defined media (14), growth inside three-dimensional scaffolds of different origin (15) and mechanical stimulation with bioreactors (16). These *in vitro* systems have been demonstrated to be effective in inducing the re-acquiring of the chondrocyte phenotype and have revealed a useful tool for researches on cartilage, but problems still remain. Chondrocyte cells maintained under conditions that enhance retention of the differentiated phenotype proliferate slower (4) and, as all cultured cells, undergo a finite number of doublings (17). To overcome these limitations, immortalized chondrocytic cell lines have been created (18). Considering the high liability of the chondrocyte phenotype, a real problem with these cell lines is the maintaining of their differentiated functions.

Recently, we developed a line of immortalized chondrocytes of human origin able to express the E6 and E7 trans-

Correspondence to: Dr Brunella Grigolo, Laboratorio di Immunologia e Genetica, Istituto di Ricerca Codivilla Putti, I.O.R., Via di Barbiano 1/10, 40136 Bologna, Italy
E-mail: grigolob@alma.unibo.it

Key words: immortalized chondrocytes, serum-free culture, hyaluronan-based scaffold

forming genes of the human papilloma virus type 16 (HPV-16) (19). These cells that during the monolayer expansion had lost their phenotypic pattern, were able to re-express cartilage typical markers when cultured in a serum-free defined medium and inside a hyaluronan-based biomaterial.

In order for a more in-depth investigation into the phenotypic modulation ability of the lbpva55 immortalized chondrocytes in these different culture conditions, we performed a quantitative gene expression analysis by means of real-time PCR technology. The genes evaluated were the main structural components of cartilage matrix (collagens I, II and aggrecan), two transcription factors regulating chondrocyte differentiation processes (Sox-9 and Egr-1) and some enzymes involved in matrix turn-over (Cathepsin B, MMP-1 and MMP-13). The presence of the main extra-cellular matrix molecules of cartilage was evaluated also by immunohistochemistry.

The data obtained with this study shed important light on our understanding of the biology of chondrocyte cells. The cell line that we developed could be a useful model system for studying both the metabolism of chondrocytes and their behaviour in a three-dimensional configuration which is known to modulate their phenotype.

Materials and methods

Cell line. The immortalized line of normal human articular chondrocytes (lbpva55) was established as previously described (19). Briefly, chondrocytes isolated from a multi-organ donor articular cartilage were transfected at $p=0$ with a plasmid carrying the HPV-16 E6 and E7 transforming genes, with a liposome-mediated procedure. The line was developed by selecting cells for their ability to escape senescence during their expansion in monolayer.

Monolayer culture and sample preparation. The lbpva55 cells (passages 60-65), seeded at high density (2×10^5 cells/cm²), were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA) with 25 mM HEPES (Sigma, St. Louis, MO, USA), 100 units/ml penicillin (Biological Industries, Israel), 100 µg/ml streptomycin (Biological Industries), 50 µg/ml gentamicin (Flow Laboratories, Biaggio, Switzerland), supplemented with 20% foetal bovine serum (FBS) (Gibco) in flasks (Costar®, Cambridge, MA, USA), at 37°C in a humidified atmosphere of 5% CO₂. The medium was changed twice a week. At confluence, cells were trypsinized, counted by eosin exclusion dye and pelleted for real-time PCR analysis or cultured in a serum-free defined medium for fourteen days. The cells were then processed for real-time PCR or grown onto a hyaluronan-based biomaterial for thirty days and then analyzed by real-time PCR technology and immunohistochemistry. Culture times of fourteen, thirty and sixty days were chosen on the basis of previous experiments performed by our group with this immortalized line and with normal articular chondrocytes (20). For each culture condition experiments were performed in triplicate.

Serum-free conditions. Confluent monolayer lbpva55 cells (DMEM supplemented with FBS 20%, passages 60-65) were

trypsinized, plated in DMEM with 10% FCS and incubated at 37°C for one day. The monolayer was rinsed with Dulbecco's Ca²⁺- and Mg²⁺-free phosphate-buffered saline (PBS) to remove serum and incubated with DMEM supplemented with 1% Nutridoma-SP (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA), a serum substitute containing insuline. Serum-free cultures were incubated for fourteen days; during this period the medium was changed twice a week and the cells were split once after eight days. At day fourteen cells were harvested and pellets processed for real-time PRC analysis.

Seeding on biomaterial. The biomaterial used as a scaffold for three-dimensional cell growth was a hyaluronan-based biopolymer termed HYAFF®-11 and obtained from F.A.B. S.r.l. (FIDIA Advanced Biopolymers, Abano Terme, Italy). Immortalized lbpva55 chondrocytes under conventional monolayer culture (passages 60-65) were trypsinized and seeded onto two 1cm² HYAFF-11 non-woven meshes at a density of 1×10^6 each, in 150 µl of culture medium in Petri dishes (Becton-Dickinson, Plymouth, UK). The cells were allowed to adhere for 8 h at 37°C and then 2 ml of DMEM with 10% FBS was added. Ascorbic acid (50 µg/ml) was added daily only to the engineered scaffold that underwent histological staining. The medium was changed twice a week. After thirty days the scaffolds were collected and one was processed for real-time PCR, while the other was used for immunohistochemical analyses.

Real-time PRC analysis. The lbpva55 cells (5×10^5) (passages 60-65) cultured on a monolayer with DMEM supplemented with 20% FCS and with medium containing 1% Nutridoma-SP for fourteen days were trypsinized, pelleted and lysed in 0.5 ml of RNeasyWIZ™ reagent (Ambion, Austin, TX, USA). HYAFF-11 scaffolds with seeded immortalized chondrocytes were collected after thirty days, placed in microcon 100 filtration devices and centrifuged at $1500 \times g$ for 5 min in order to remove the liquid medium. Cells were lysed directly in the culture scaffold by the addition of 0.5 ml of RNeasyWIZ reagent.

Total RNA was subsequently isolated from the samples using the single-step guanidinium thiocyanate-phenol-chloroform method. Complementary DNA was synthesized from 1 µg of total RNA per sample with 45-min incubation at 42°C, using Moloney Murine leukemia virus reverse transcriptase (Perkin Elmer, Norwalk, CT, USA) and oligo-(dT) priming. PCR primers for aggrecan and for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as endogenous control, were obtained from published references (21,22). PCR primers for cathepsin B, collagens I and II, Egr-1, MMP-1, MMP-13 and Sox-9, were designed by our group (23-25).

Real-time PCR was run in a LightCycler instrument (Roche Molecular Biochemicals, Mannheim, Germany) using the QuantiTect™ SYBR®-Green PCR kit (Qiagen, GmbH, Germany). Cycling parameters were: 15 min at 94°C (initial activation of HotStarTaq™ DNA polymerase) followed by 45 cycles of 15 sec at 94°C, 20 sec at 56°C/58°C/60°C (depending on primer pair) and 10 sec at 72°C. The increase in PCR product was monitored for each amplification cycle

by measuring the increase in fluorescence caused by the binding of SYBR-Green I dye to dsDNA. The threshold cycle (C_T) values (i.e. the cycle numbers at which the detected fluorescence reaches a threshold value in the range of exponential amplification) were determined for each sample and specificity of the amplicons was confirmed by melting curve analysis and agarose gel electrophoresis. To analyze data from real-time PCR we used the 'comparative C_T method' previously described by Livak (26). As a relative quantification method, it relates the PCR signal of each target gene obtained in the samples (or sample groups) to that of a reference control (or reference control group) using the formula $2^{-\Delta\Delta C_T}$. In this case the monolayer cultured immortalized lbpva55 cells were considered the control group and the cells cultured in serum-free conditions for fourteen days and grown inside the HYAFF-11 biomaterial for thirty days were the sample groups. For each sample, ΔC_T represents the difference between C_T of each target gene and the internal control gene (GAPDH). For each specific gene $\Delta\Delta C_T$ represents the difference between ΔC_T of the different samples and the control. For each control sample $\Delta\Delta C_T=0$ and $2^0=1$, by definition. Using this method, the data are presented as differences in gene expression (relative gene expression) normalized to an endogenous reference gene and relative to a control group.

Statistical analysis. Statistical computations were performed using CSS Statistica-Statistical software (Statsoft Inc. Tulsa, OK, USA). All values were expressed as the mean \pm standard deviation (SD). Quantitative parameters were compared by means of the Wilcoxon matched pairs non-parametric test. Differences were considered as significant when $p<0.05$.

Immunohistochemistry. For immunohistochemical analysis the following primary antibodies were used: mouse monoclonal anti-human collagen type I (Chemicon International, Temecula, CA, USA), mouse monoclonal anti human collagen type II (Chemicon International), mouse monoclonal anti-human proteoglycans (Chemicon International) and goat affinity purified polyclonal anti-human cathepsin B (Santa Cruz Biotechnology, Inc.). HYAFF-11 engineered scaffolds were embedded in OCT and snap-frozen in liquid nitrogen. The specimens were then sectioned into 5- μ m sections, air dried and stored at -80°C . At analysis the slides were transferred at room temperature, air dried for 15 min and fixed in methanol/acetone at 4°C for 20 and 10 min respectively. Air-dried fixed samples were rehydrated and, for epitope unmasking, were treated with 0.1% hyaluronidase (Sigma) in phosphate buffered saline (PBS) at 37°C for 5 min. After washing, for the detection of type I and II collagens the slides were incubated at room temperature for 30 min in X1 PBS containing 5% normal goat serum (NGS) (Dako, Carpinteria, CA, USA), while normal rabbit serum (NRS) (Dako) was used for cathepsin B, to prevent non-specific binding. The slides were incubated with anti-human collagen type I, collagen type II, proteoglycans and cathepsin B, primary antibodies diluted 1:20, 1:20, 1:50 and 1:200 respectively in 0.04 M Trizma base saline (TBS), pH 7.6, containing 1% bovine serum albumin (BSA) and 0.1% Triton X-100 for 1 h at room temperature. For the detection of type I and II




Figure 1. Quantitative real-time PCR analysis of differential gene expression levels of collagen I (A), collagen II (B) and aggrecan (C) in immortalized chondrocytes (lbpva55 line) cultured in a conventional monolayer condition, in serum-free cultures (14 days) and grown onto HYAFF-11 biomaterial (30 days). Results are reported as relative gene expression and calculated by the formula $2^{-\Delta\Delta C_T}$. The $2^{-\Delta\Delta C_T}$ value represents the difference between C_T of each target gene and the internal control (GAPDH). The $\Delta\Delta C_T$ value for each specific gene represents the difference between ΔC_T values for all the experimental times evaluated and the ΔC_T value obtained on day 1. Using this method, the $\Delta\Delta C_T$ value obtained on day 1 = zero and $2^0=1$, by definition. Monolayer vs serum free, * $p<0.05$; serum free vs biomaterial, ** $p<0.05$; monolayer vs biomaterial, *** $p<0.05$. Values are expressed as mean \pm standard deviation (SD).

collagens and proteoglycans slides were washed three times with 0.04 M TBS, pH 7.6, and incubated with goat anti-mouse and anti-rabbit immunoglobulins labelled with dextran molecules-alkaline phosphatase (Dako) at room temperature for 30 min. For cathepsin B immunostaining anti-goat-biotin conjugated rabbit immunoglobulins (Pierce, Rockford, IL, USA) diluted 1:200 in TBS 0.04 M, pH 7.6,




Figure 2. Quantitative real-time PCR analysis of differential gene expression levels of Sox-9 (A) and Egr-1 (B) in immortalized chondrocytes (Ibpva55 line) cultured in conventional monolayer condition, in serum-free cultures (14 days) and grown onto HYAFF-11 biomaterial (30 days). Results are reported as relative gene expression and calculated by the formula $2^{-\Delta\Delta C_T}$. The ΔC_T value represents the difference between C_T of each target gene and the internal control (GAPDH). The $\Delta\Delta C_T$ value for each specific gene represents the difference between ΔC_T values for all the experimental times evaluated and the ΔC_T value obtained on day 1. Using this method, the $\Delta\Delta C_T$ value obtained on day 1 = zero and $2^0=1$, by definition. Monolayer vs serum free, * $p<0.05$; serum free vs biomaterial, ** $p<0.05$; monolayer vs biomaterial, *** $p<0.05$. Values are expressed as mean \pm standard deviation (SD).

were used and a further incubation of 1 h at room temperature with a streptavidin-alkaline phosphatase conjugate (Boehringer) was also performed. After three washes with 0.04 M TBS, pH 7.6, the reactions were developed using a new fucsin kit (kit new fucsin substrate system, Dako) in the presence of 5 mM levamisole (Sigma) to block endogenous alkaline phosphatase. Negative controls were performed by omitting the primary antibody. Slides were counterstained with hematoxylin and mounted in glycerol gel. All the samples were analysed using a Zeiss axioscope microscope (Carl Zeiss, Oberkochen, Germany).

Results

Real-time PCR analysis. Real-time PCR results, calculated using the ΔC_T method as described in Materials and methods,




Figure 3. Quantitative real-time PCR analysis of differential gene expression levels of cathepsin B (A), MMP-1 (B) and MMP-13 (C) in immortalized chondrocytes (Ibpva55 line) cultured in conventional monolayer condition, in serum-free cultures (14 days) and grown onto HYAFF-11 biomaterial (30 days). Results are reported as relative gene expression and calculated by the formula $2^{-\Delta\Delta C_T}$. The ΔC_T value represents the difference between C_T of each target gene and the internal control (GAPDH). The $\Delta\Delta C_T$ value for each specific gene represents the difference between ΔC_T values for all the experimental times evaluated and the ΔC_T value obtained on day 1. Using this method, the $\Delta\Delta C_T$ value obtained on day 1 = zero and $2^0=1$, by definition. Monolayer vs serum free, * $p<0.05$; serum free vs biomaterial, ** $p<0.05$; monolayer vs biomaterial, *** $p<0.05$. Values are expressed as mean \pm standard deviation (SD).

and evaluated as relative gene expression, are shown in Figs. 1-3. Collagen I mRNA was detected in all the culture conditions evaluated. Its expression showed a significant increase in the chondrocytes cultured under serum-free conditions in comparison to the cells expanded in monolayer (6.6-fold) and




Figure 4. Collagen II (left upper panel), collagen I (right upper panel), proteoglycans (left lower panel) and cathepsin B (right lower panel) immunostaining of immortalized chondrocytes (Ibpa55) seeded on HYAFF-11 at day 60. All samples were developed using new fuchsin (red, positive stain). HYAFF-11 fibers are indicated with white arrows.

grown onto the biomaterial (5.1-fold). Values were slightly higher (0.3 fold difference) for the HYAFF-11 engineered cells compared to the monolayer condition (Fig. 1A). Collagen II mRNA was undetectable in the monolayer cultured chondrocytes. For this reason, the ΔC_T analysis for this gene was performed comparing only the serum-free and the scaffold cultures. The results showed that, when the cells were cultured in the two re-differentiating conditions tested, they started to re-express collagen II mRNA and that its levels were significantly higher (35.8-fold) for the HYAFF-11 cultures compared to the Nutridoma-SP ones (Fig. 1B). Aggrecan mRNA was present in all the culture models studied. In comparison with the monolayer cultured cells, it showed a decrease that was significant (7-fold) in serum-free condition and slight (1.2-fold) for the engineered scaffolds. Gene expression levels were significantly lower in Nutridoma-SP compared to the biomaterial cultures (5-fold) (Fig. 1C). Sox-9 mRNA was expressed in the monolayer condition and showed a significant increase both in the Nutridoma-SP (5.1-fold) and in the HYAFF-11 (2.1-fold) cultures. Its values were significantly higher (2.4-fold) in serum-free cultured chondrocytes in comparison with the engineered ones (Fig. 2A). Egr-1 expression significantly decreased in serum-free conditions (3.4-fold) and in the engineered scaffolds (16.6-

fold) in comparison with the monolayer cultured chondrocytes. Values were significantly higher (4.8-fold) for the cells cultured with Nutridoma-SP compared to the ones grown inside the biomaterial (Fig. 2B). Cathepsin B, MMP-1 and MMP-13 mRNAs were detected in all the experimental conditions evaluated (Fig. 3A, B and C, respectively). Their expression was significantly higher in the serum-free cultures both in comparison with the monolayer ones (2.4-, 125- and 6.6-fold, respectively) and with the HYAFF-11 engineered chondrocytes (3.2-, 16.8- and 55-fold, respectively). For the cells cultured onto the biomaterial values were lower for cathepsin B (1.3-fold), significantly lower (8.3-fold) for MMP-13 and significantly higher for MMP-1 (7.4-fold), in comparison with the monolayer cultures.

Immunohistochemical analysis. To verify the re-acquisition of the chondrocyte phenotype in the immortalized engineered scaffolds, the production of collagens II and I, proteoglycans and cathepsin B was evaluated by immunohistochemistry (Fig. 4). The analyses, performed after thirty days of culture, showed a strong positivity for collagen type II, while collagen type I was completely undetectable. The occurrence of a re-differentiation process was also confirmed by an evident matrix staining for proteoglycans and a weak positivity for cathepsin B.

Discussion

Studies with articular chondrocytes have been hampered by the high instability of the cartilage-specific phenotype when cells are cultured in monolayer (4-8). Among the various directions that have been explored to overcome this limitation, the generation of stable lines of immortalized chondrocytes is becoming more and more a reality, due also to improvements in the transformation protocols which have allowed the creation of immortalized cells from pathologic tissue (18).

We previously established a line of immortalized normal human articular chondrocytes, lbpva55, expressing the E6 and E7 transforming genes of the HPV-16 (19). These cells lost their phenotypic pattern during the monolayer expansion, but demonstrated the ability to re-express the main cartilage markers when cultured in a serum-free defined medium and inside a three-dimensional scaffold, two culture models which were known to allow chondrocyte re-differentiation (14,15). In fact, we chose a serum substitute already used for immortalized chondrocytes (27) and containing insulin which may replace insulin-like growth factor-I (IGF-I), an anabolic growth factor involved in the maintenance of articular cartilage phenotypic expression (28,29). As a scaffold for the cells we chose a hyaluronan-based three-dimensional biomaterial, HYAFF-11, which had been previously used by our group for chondrocyte transplantation in rabbits (30) and tested for its ability to allow the *in vitro* re-differentiation of normal human cartilage cells (20). The clinical use of this scaffold in the autologous chondrocyte transplantation procedure for the repair of cartilage defects in humans is well documented (31,32).

In order to investigate the phenotypic modulation ability of the immortalized chondrocytes in more depth, we performed a quantitative real-time PCR analysis which allowed the quantification of the differences in gene expression between the cells cultured in monolayer and in these two re-differentiating conditions.

The results of the present study indicate that HYAFF-11 is more suitable in inducing the re-differentiation process in accordance with those obtained by our group with the same biomaterial seeded with normal human articular chondrocytes (20). This is confirmed by the expression of cartilage markers and by the presence of specific transcription factors such as Sox-9 and Egr-1 which are known to be involved in the modulation of chondrocyte phenotypic gene expression. Sox-9 is a member of the family of Sox (Sry-type high-mobility group box transcription factor) genes and contains a high mobility group DNA-binding domain (33). It has been demonstrated to play an essential role in the commitment of mesenchymal cells to the chondrogenic lineage and in the process of chondrocyte differentiation. Its presence is required for the expression of a series of chondrocyte-specific marker genes including collagen II and aggrecan (34). However, its role has not been thoroughly clarified (35). What was surprising for us was that Sox-9 mRNA levels were higher in the Nutridoma-SP cultures than in the HYAFF-11 cultures where collagen II and aggrecan levels were significantly greater. A lack of positive correlation between Sox-9 and collagen II expression has been already

demonstrated in adult human articular chondrocytes (37). Moreover, some authors (36) found that the overexpression of Sox-9 induces an inhibition of collagen II in rabbit articular chondrocytes. The early growth response (Egr-1) transcription factor belongs to the class of immediate early genes (35). It is a serum-inducible zinc finger protein that has been demonstrated to be crucial in the regulation of growth factors, hormones, cytokines and adhesion molecules (38). It has been shown that Egr-1 is highly expressed in primary human articular chondrocytes (39) and lower expression levels have been found in osteoarthritic cartilage (40). However, the role of Egr-1 remains controversial, since it can act both as a transcriptional activator and as a suppressor (38) and target genes in chondrocyte differentiation have not been well identified. Egr-1 has been suggested to serve as a transcriptional suppressor for collagen II by preventing interactions between Sp1 and the transcriptional machinery (41). This finding is in accordance with our results: higher levels in the monolayer cultures where no collagen II expression was detected and decreased levels both in the serum-free and in the scaffold cultures, thus confirming a re-activation of the transcriptional mechanisms involved in chondrocyte differentiation. Moreover, since it is known that Egr-1 is transiently induced by serum (42), the higher levels observed in the immortalized chondrocytes cultured in monolayer are likely to be due to the presence of 20% FBS in the medium. In fact, these levels decreased in the scaffold cultures where FBS was present at a 10% concentration and in serum-free conditions where serum was completely depleted. However, mRNA levels were significantly higher in the Nutridoma-SP cultures compared with the HYAFF-11 cultures. This could be attributed to the reported ability of insulin to induce Egr-1 expression (43).

Finally, we analyzed the expression of two cartilage matrix metalloproteinases (MMPs), fibroblast collagenase (MMP-1) and collagenase 3 (MMP-13), which are members of a large family of proteinases that have several structural features in common, including the presence of a conserved zinc-binding catalytic domain (44). In particular, MMP-1 and -13 which are able to degrade native triple-helical collagen by cleaving at the collagenase site, have been demonstrated to play a major pathological role in the cartilage destruction of osteoarthritis (45). We found that the gene expression levels of the two MMPs were detectable in all the culture conditions evaluated, as already observed *in vitro* for both normal and immortalized human articular chondrocytes (46,47). A significant up-regulation was observed in the Nutridoma-SP cultures, while the engineered cells displayed lower levels. The ability of the hyaluronan-based HYAFF-11 scaffold to reduce the expression of molecules involved in cartilage degeneration in normal human articular chondrocytes has been already demonstrated by our group (25). It seems that the lbpva55 cells also benefit from the presence of the hyaluronan molecule that operates on chondrocyte metabolism activating anabolic pathways (48).

Since our experiments were performed under static conditions, further studies need to be conducted in a mechanically active environment such as a bioreactor. Bioreactors have become an important tool for tissue engineering as they provide both the technological means to

reveal the fundamental mechanisms of cell function in a three-dimensional environment, and the potential to improve the quality of engineered tissues (49). Particularly, it would be interesting to evaluate of the differences in gene expression of immortalized human chondrocyte cells under different physical stimula.

Acknowledgments

We thank Patrizia Rappini and Graziella Salmi for assistance in the preparation of the manuscript and Luciano Pizzi for his technical assistance. We also thank Mr. Keith Smith for revising the paper.

References

- Green WT: Behaviour of articular chondrocytes in cell culture. *Clin Orthop* 75: 248-260, 1971.
- Goldring MB: Human chondrocyte cultures as models of cartilage-specific gene regulation. *Methods Mol Med* 107: 69-96, 2004.
- Goldring MB: Culture of immortalized chondrocytes and their use as models of chondrocyte function. *Methods Mol Med* 100: 37-52, 2004.
- Kolettas E, Buluwela L, Bayliss MT and Muir HI: Expression of cartilage-specific molecules is retained on long-term culture of human articular chondrocytes. *J Cell Sci* 108: 1991-1995, 1995.
- Archer C, McDowell J, Bayliss M, Stephens M and Bentley G: Phenotypic modulation of sub-populations of human articular chondrocytes *in vitro*. *J Cell Sci* 97: 361-371, 1990.
- Swoboda B, Holmdahl R, Stoss H and von der Mark K: Cellular heterogeneity in cultured human chondrocytes identified by antibodies specific for alpha 2(XI) collagen chains. *J Cell Biol* 109: 1363-1369, 1989.
- Aulthouse AL, Beck M, Griffey E, Sanford J, Arden K, Machado MA, Aulthouse AL, Ahmed S and Ellard JT: Expression of the human chondrocyte phenotype *in vitro*. *In Vitro Cell Dev Biol* 25: 659-668, 1989.
- Baici A, Lang A, Hörler D and Knöpfel M: Cathepsin B as a marker of the dedifferentiated chondrocyte phenotype. *Ann Rheum Dis* 47: 684-691, 1988.
- Benya PD, Padilla SR and Mimni ME: Independent regulation of collagen types by chondrocytes during the loss of differentiated function in culture. *Cell* 15: 1313-1321, 1978.
- von der Mark K, Gauss V, von der Mark H and Muller P: Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. *Nature* 267: 531-532, 1977.
- Darling EM and Athanasian KA: Rapid phenotypic changes in passaged articular chondrocyte subpopulations. *J Orthop Res* 23: 425-432, 2005.
- Grandolfo P, D'Andrea P, Paoletti M, Martina M, Silvestrini E, Bonucci E and Fittur F: Culture and differentiation of chondrocytes entrapped in alginate beads. *Calcif Tissue Int* 52: 42-48, 1993.
- Zhang Z, McCaffery JM, Spencer RG and Francomano CA: Hyaline cartilage engineered by chondrocytes in pellet culture: histological, immunohistochemical and ultrastructural analysis in comparison with cartilage explants. *J Anat* 205: 229-237, 2004.
- Taub M: The use of defined media in cell and tissue culture. *Toxic in Vitro* 4: 213-225, 1989.
- Freed L, Marquis JC, Nohria A, Emmanuel J, Mikos AG and Langer R: Neocartilage formation *in vitro* and *in vivo* using cells cultured on synthetic biodegradable polymers. *J Biomed Mat Res* 27: 11-23, 1993.
- Lee DA and Martin I: Bioreactor culture techniques for cartilage tissue engineering. *Methods Mol Biol* 238: 159-170, 2004.
- Haudenschild DR, McPherson JM, Tubo R and Binette F: Differential expression of multiple genes during articular chondrocyte redifferentiation. *Anat Rec* 263: 91-98, 2001.
- Yoshimatsu T, Saitoh A, Ryu JN, Shima D, Handa H, Hiramoto M, Kawakami Y and Aizawa S: Characterization of immortalized human chondrocytes originated from osteoarthritis cartilage. *Int J Mol Med* 8: 345-351, 2001.
- Grigolo B, Roseti L, Neri S, Gobbi P, Jensen P, Major EO and Facchini A: Human articular chondrocytes immortalized by HPV-16 E6 and E7 genes: Maintenance of differentiated phenotype under defined culture conditions. *Osteoarthritis Cartilage* 10: 879-889, 2002.
- Grigolo B, Lisignoli G, Piacentini A, Fiorini M, Gobbi P, Mazzotti G, Duca M, Pavesio A and Facchini A: Evidence for redifferentiation of human chondrocytes grown on a hyaluronan-based biomaterial (Hyaff-11): molecular, immunohistochemical and ultrastructural analysis. *Biomaterials* 3: 1187-1195, 2001.
- Martin I, Jakob M, Schäfer D, Dick W, Spagnoli G and Heberer M: Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. *Osteoarthritis Cartilage* 9: 112-118, 2001.
- Blanco FJ, Geng Y and Lotz M: Differentiation-dependent effects of IL-1 and TGF- β on human articular chondrocyte proliferation are related to inducible nitric oxide synthase expression. *J Immunol* 154: 4018-4026, 1995.
- Grigolo B, Roseti L, Fiorini M, Piacentini A, De Franceschi L and Facchini A: Cathepsin B as a soluble marker to monitor the phenotypic stability of engineered cartilage. *Biomaterials* 24: 1751-1757, 2003.
- Grigolo B, Roseti L, De Franceschi L, Piacentini A, Cattini L, Manfredini M, Faccini R and Facchini A: Molecular and immunohistological characterization of human cartilage two years following autologous cell transplantation. *J Bone Joint Surg Am* 87: 46-57, 2005.
- Grigolo B, De Franceschi L, Roseti L, Cattini L and Facchini A: Down regulation of degenerative cartilage molecules in chondrocytes grown on a hyaluronan-based scaffold. *Biomaterials* 26: 5668-5676, 2005.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using Real-Time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods* 25: 402-408, 2001.
- Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser JL and Apperley JF: Interleukin-1 β modulated gene expression in immortalized human chondrocytes. *J Clin Invest* 94: 2307-2316, 1994.
- Fortier LA, Deak MM, Semevolos SA and Cerione RA: Insulin-like growth factor-I diminishes the activation status and expression of the small GTPase Cdc42 in articular chondrocytes. *J Orthop Res* 22: 436-445, 2004.
- Loeser RF, Pacione CA and Chubinskaya S: The combination of insulin-like growth factor 1 and osteogenic protein 1 promotes increased survival of and matrix synthesis by normal and osteoarthritic human articular chondrocytes. *Arthritis Rheum* 48: 2188-2196, 2003.
- Grigolo B, Roseti L, Fiorini M, Fini M, Giavaresi G, Nicoli Aldini N, Giardino R and Facchini A: Transplantation of chondrocytes seeded on a hyaluronan derivative (Hyaff[®]-11) into cartilage defects in rabbits. *Biomaterials* 22: 2417-2424, 2001.
- Marcacci M, Zaffagnini S, Kon E, Visani A, Iacono F and Loret L: Arthroscopic autologous chondrocyte transplantation: technical note. *Knee Surg Sports Traumatol Arthrosc* 10: 154-159, 2002.
- Marcacci M, Berruto M, Brocchetta D, Delcogliano A, Ghinelli D, Gobbi A, Kon E, Pederzini L, Rosa D, Sacchetti DL, Stefani G and Zanasi S: Articular cartilage engineering with Hyalograft C: 3-year clinical results. *Clin Orthop* 435: 96-105, 2005.
- Davies SR, Sakano S, Zhu Y and Sandell LJ: Distribution of the transcription factors SOX9, AP-2, and Δ EF1 in adult murine articular and meniscal cartilage and growth plate. *J Histochem Cytochem* 50: 1059-1065, 2002.
- Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A and Noda M: SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell TC6. *J Biol Chem* 275: 10738-10744, 2000.
- Aigner T, Gebhard PM, Schmid E, Bau B, Harley V and Poschl E: SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes. *Matrix Biol* 22: 363-372, 2003.
- Kypriotou M, Fossard-Demoor M, Chadchistos C, Ghayor C, de Crombrughe B, Pujol JP and Galera P: SOX9 exerts a bifunctional effect on type II collagen gene (COL2A1) expression in chondrocytes depending on the differentiation state. *DNA Cell Biol* 22: 19-29, 2003.
- Sukhatme VP, Kartha S, Toback FG, Taub R, Hoover RG and Tsai-Morris CH: A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. *Oncogene Res* 1: 343-355, 1987.

38. Khachigian LM and Collins T: Early growth response factor 1: a pleiotropic mediator of inducible gene expression. *J Mol Med* 76: 613-616, 1998.
39. Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vecsei V and Schlegel J: Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. *Osteoarthritis Cartilage* 10: 62-70, 2002.
40. Wang FL, Connor JR, Dodds RA, James IE, Kumar S, Zou C, Lark MW, Gowen M and Nuttall ME: Differential expression of Egr-1 in osteoarthritic compared to normal adult human articular cartilage. *Osteoarthritis Cartilage* 8: 161-169, 2000.
41. Tan L, Peng H, Osaki M, Choy BK, Auron PE, Sandell LJ and Goldring MB: Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1 β . *J Biol Chem* 278: 17688-17700, 2003.
42. Christy BA, Lau LF and Nathans D: A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with 'zinc finger' sequences. *Proc Natl Acad Sci USA* 85: 7857-7861, 1988.
43. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, Cohen DR, Edwards SA, Shows TB and Curran T: A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarisation. *Cell* 53: 37-43, 1988.
44. Nagase H and Woessner JF Jr: Matrix metalloproteinases. *J Biol Chem* 274: 21491-21494, 1999.
45. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J and Clark I: Matrix metalloproteinases in arthritic disease. *Arthritis Res* 4: S39-S49, 2002.
46. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T: Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes *in vivo* and *in vitro*. *Arthritis Rheum* 46: 2648-2657, 2002.
47. Robbins JR, Thomas B, Tan L, Choy B, Arbisser JL, Berenbaum F and Goldring MB: Immortalized human adult articular chondrocytes maintain cartilage-specific phenotype and responses to interleukin-1 β . *Arthritis Rheum* 43: 2189-2201, 2000.
48. Knudson CB and Knudson W: Hyaluronan and CD44: modulators of chondrocyte metabolism. *Clin Orthop* 427: S152-S162, 2004.
49. Démariseau O, Jakob M, Schäfer D, Heberer M and Martin I: Development and validation of a bioreactor for physical stimulation of engineered cartilage. *Biorheology* 40: 331-336, 2003.